Biotech Showcase™ 2016: Interview: Renova develops gene therapies for CHF and type 2 diabetes

February 10, 2016
Renova Therapeutics co-founder and CEO Dr. Jack Reich tells Informa Pharma Insights director of global content Mike Ward how his company is developing once-in-a-lifetime gene therapies to treat both congestive heart failure and type 2 diabetes. The lead program, designed to revive AC6 levels to restore heart function to normal levels, has completed a Phase II trial in collaboration with NIH in a public-private partnership. The company is now planning to run a Phase III trial in the European Union and US by the end of 2016. In addition, Reich explains how second generation gene therapies that can be administered through intravenous injection, targeting CHF and type II diabetes, are expected to be put into clinical trials later this year. Find more videos and articles at http://www.partnering360.com/insight For more information on Biotech Showcase™, visit our webpage: http://www.ebdgroup.com/bts/index.php
Previous Video
Biotech Showcase™ 2016: Interview: Enumeral aspires to take PD-1 inhibition to the next level
Biotech Showcase™ 2016: Interview: Enumeral aspires to take PD-1 inhibition to the next level

Enumeral CEO Arthur Tinkelenberg explains his company’s human-driven immune profiling platform and how it c...

Next Video
Biotech Showcase™ 2016: Interview: Diagnostics company VisionGate migrates into therapeutics
Biotech Showcase™ 2016: Interview: Diagnostics company VisionGate migrates into therapeutics

VisionGate founder, chairman and CEO Dr. Alan Nelson explains to Mike Ward, Informa Pharma Insights global ...